Inspire Medical Systems, Inc. (INSP) Aandelenanalyse

Bedrijfsoverzicht

Inspire Medical Systems, Inc. is a medical technology enterprise dedicated to the development and commercialization of minimally invasive solutions designed to treat obstructive sleep apnea (OSA) for patients in the United States and international markets. The company operates within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on high-barrier-to-entry manufacturing, regulatory compliance, and specialized technological innovation. Inspire Medical Systems, Inc. currently holds a market capitalization of $1.56B and generates annual revenue of $911.98M while employing a workforce of 1333 individuals. These financial figures indicate that the company has established a substantial presence in its niche, possessing significant market equity that reflects investor confidence in its established product portfolio and operational scale.

Financiële gezondheid

The company reported revenue of $911.98M over the trailing twelve months, resulting in a net income of $145.42M and an EBITDA of $64.91M. The substantial gap between the total revenue and net income reveals a robust cost structure where operating expenses and taxes consume approximately 84% of top-line sales, yet the company maintains a highly profitable bottom line. Free cash flow stands at $54.50M, which signifies that the business generates sufficient liquidity from operations to cover capital expenditures and fund ongoing R&D or strategic initiatives without requiring external financing. Gross margin is reported at 85.4%, operating margin at 17.1%, and profit margin at 15.9%, indicating that the company retains a very high portion of revenue after cost of goods sold and maintains strong efficiency in converting sales into operational and net profit. The balance sheet shows a cash position of $308.27M against total debt of $32.16M, supported by a debt-to-equity ratio of 4.12, which suggests a conservative balance sheet with ample liquidity to service obligations despite the high leverage ratio relative to equity. Current ratio is 6.08, demonstrating exceptional short-term liquidity as current assets are more than six times current liabilities, ensuring the ability to meet immediate financial obligations. Return on Equity is 19.8% and Return on Assets is 3.7%, revealing that management is highly effective at generating shareholder value from equity investments, while asset turnover efficiency is moderate, typical for capital-intensive medical device manufacturing.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is 11.05, while the forward P/E is 20.75, implying that the market expects earnings to grow significantly in the coming year to justify the higher multiple on future projections. The price-to-book ratio stands at 1.98, indicating that the stock trades at a market premium of nearly double its book value, reflecting the high intangible value of its intellectual property and technology. Alternative valuation metrics include a price-to-sales ratio of 1.71 and an EV/EBITDA of 19.54, which suggest the market values the company based on its revenue generation and earnings power relative to enterprise value. The stock's 52-week trading range spans from a low of $48.30 to a high of $163.35, placing the current valuation context within this historical volatility band. With a beta of 0.86, the company exhibits price volatility that is lower than the broader market average, suggesting it may move less dramatically than the overall index during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year is 12.2%, while earnings growth year-over-year is 308.4%, indicating that earnings are expanding at a rate significantly faster than revenue, which often points to leverage effects, cost efficiencies, or one-time income items impacting the bottom line disproportionately. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it retains all earnings to reinvest into research, development, and business expansion rather than distributing cash to shareholders. This reinvestment strategy aligns with the growth profile of a medical device firm in a specialized therapeutic area where capital allocation toward innovation is critical for maintaining competitive advantage. Overall, the company presents a growth-oriented financial profile characterized by accelerating earnings relative to revenue and a capital retention policy that supports long-term technological development rather than current income distribution.